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ABSTRACT
Background: Medullary thyroid cancer (MTC) comprises only 4% of all thyroid 
cancers and originates from the parafollicular C-cells. HIF-1α expression has been 
implied as an indicator of worse prognosis in various solid tumors. However, whether 
expression of HIF-1α is a prognosticator in MTC remained unclear. Our aim was to 
evaluate the prognostic value of HIF-1α in patients with MTC.
Methods: All patients with MTC who were operated on between 1988 and 2014 
in five tertiary referral centers in The Netherlands were included. A tissue microarray 
was constructed in which 111 primary tumors could be analyzed for expression of 
HIF-1α, CAIX, Glut-1, VEGF and CD31 and correlated with clinicopathologic variables 
and survival.
Results: The mean age of patients was 46.3 years (SD 15.6), 59 (53.2%) were 
male. Of the 111 primary tumors, 49 (44.1%) were HIF-1α negative and 62 (55.9%) 
were HIF-1α positive. Positive HIF-1α expression was an independent negative 
indicator for progression free survival (PFS) in multivariate cox regression analysis 
(HR 3.1; 95% CI 1.3 – 7.3). Five-years survival decreased from 94.0% to 65.9% for 
the HIF-1α positive group (p=0.007). Even within the group of patients with TNM-
stage IV disease, HIF-1α positivity was associated with a worse prognosis, shown by 
a decrease in 5-years survival of 88.0% to 49.3% (p=0.020).
Conclusion: Expression of HIF-1α is strongly correlated with adverse prognosis 
of MTC. This could open up new ways for targeted systemic therapy of MTC.




Medullary thyroid cancer (MTC) accounts for 4% 
of all thyroid cancers and, in contrast to other forms of 
thyroid cancer, it arises from the parafollicular C-cells. 
It occurs either as a sporadic disease or in a hereditary 
context as a manifestation of the endocrine tumor 
syndrome Multiple Endocrine Neoplasia type 2 (MEN2) 
(20-25%) [1]. Hereditary tumors are characterized by 
activating mutations in the rearranged-during-transfection 
(RET) proto-oncogene. Sporadic MTCs harbor, in 50% of 
cases, an acquired mutation in the RET proto-oncogene. 
About 45% of all patients present with advanced disease 
(stage III-IV), which has a 10-year survival rate of 71% 
and 21%, respectively [2].
Currently, clinical variables such as age, extent of 
the primary tumor, lymph node metastases and distant 
metastases have been identified as prognostic factors 
[2]. No further stratification for stage III-IV patients 
is available, while prognosis within these groups can 
vary widely [3]. To set the indication for follow-up or 
adjuvant treatment, patients with poor prognosis need to 
be identified, especially within the subgroup of stage III-
IV patients.
Hypoxia inducible factor-1 (HIF-1) is the key 
regulator of the hypoxia response. HIF-1 is a protein 
complex composed of two subunits; constitutive HIF-
1β and oxygen-sensitive HIF-1α. HIF-1α can either be 
upregulated due to oncogenic signaling or as a response 
to tumor hypoxia. Under normal conditions the HIF-1α 
subunit is degraded by the ubiquitin-proteasome pathway. 
Under hypoxia or as a result of oncogenic signaling, 
degradation is inhibited resulting in its accumulation, 
subsequent binding to HIF-1β, translocation to the nucleus 
and activation of downstream signaling pathways by 
binding to hypoxia responsive elements in the promoters 
of target genes [4–9]. Increased expression of HIF-1α in 
tumor cells, whether induced by hypoxia or by aberrant 
oncogenic signaling, actively drives tumor growth and 
progression by regulating the expression of crucial target 
genes such as vascular endothelial growth factor (VEGF), 
carbonic anhydrase IX (CAIX) and glucose transporter 1 
(Glut-1) [8, 10].
In this regard, the importance of HIF-1α and its 
downstream targets has been investigated in various solid 
tumors, and the correlation of high HIF-1α expression 
with poor prognosis has been well established [10]. In 
sporadic MTC, expression of HIF-1α has been reported 
in 89% of tumors, and associated with clinical features, as 
lymph node positivity, higher T-stage and extrathyroidal 
extension, which are known to adversely affect prognosis 
[11]. However, due to the lack of survival data, prognostic 
value of HIF-1α in MTC could not be determined. Our 
aim was therefore to investigate the prognostic value of 
HIF-1α expression in MTC.
RESULTS
Clinicopathologic variables
The mean age of the 111 patients was 46.3 years (SD 
15.6), 59 (53.2%) were male. Sixty-five patients (60.2%) 
had a sporadic medullary thyroid carcinoma, 39 patients 
(36.1%) had MEN2a and 4 patients (3.7%) had MEN2b, 
from 3 patients the RET-mutation status was unknown. 
Fifteen patients presented with stage 1 (13.5%), 26 with 
stage II (23.4%), 17 (15.3%) with stage III and 53 (47.7%) 
with stage IV disease. Median tumor size was 25.6 mm 
(IQR 25; minimum 2 mm; maximum 80 mm) and 79 
(63.1%) patients presented with lymph node metastases. 
Mean follow-up was 79.2 months (SD 60.6).
Association between HIF-1α expression and 
clinicopathologic variables
Forty-nine (44.1%) patients were HIF-1α negative 
and 62 (55.9%) HIF-1α positive. In univariate analysis, 
age, gender, heritability, stage, tumor size, lymph node 
metastases, disease status, microvessel density (MVD) 
and presence of necrosis or angioinvasion did not differ 
significantly between HIF-1α negative and positive groups 
(Table 1). For overall survival (OS) and PFS a significant 
association with HIF-1α status was found. Forty-six 
(93.9%) patients in the HIF-1α negative versus 49 (79.0%) 
patients in the HIF-1α positive group survived (p = 0.03). 
Forty-two (85.7%) patients in the HIF-1α negative versus 
38 (61.3%) patients in the HIF-1α positive group did 
not show progression, i.e. they did not develop distant 
metastasis (p = 0.01). Grade of desmoplasia correlated 
significantly with HIF-1α expression, in the moderate 
to severe group 40 patients (66.7%) showed HIF-1α 
positivity (p = 0.00). CAIX, Glut-1 and VEGF showed a 
positive correlation with HIF-1α, with an OR of 1.5, 4.2 
and 1.4 respectively, however, this correlation was not 
significant (Table 1).
Prognostic value
To verify which variables were associated with 
PFS and OS a univariate survival analysis was performed 
(Table 2). For PFS a significant association was found 
for TNM-stage, presence of lymph node metastasis, 
heritability, HIF-1α, necrosis and Glut-1. For OS an 
association was found for heritability, disease status, 
necrosis, HIF-1α and VEGF. Our total number of events, 
patients that developed metastases and/or died, (n = 33) 
restricted us in the number of variables for multivariate 
analysis; therefore we studied in a Cox regression analysis 
the association of HIF-1α, TNM-stage and heritability on 
PFS. The variable lymph node metastasis was left out of 
the Cox regression analysis since this is also taken into 
account by the TNM-stage; disease status was left out 
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Table 1: Clinicopathological characteristics of all patients stratified by HIF-1α status
 
 
HIF-1α neg HIF-1α pos  
 N=49 N=62
Mean age in years (SD) 45.0 (14.1) 47.2 (16.7) 0.46
Gender     0.71
 Male (%) 25 (51.0) 34 (54.8)  
Heritability     0.33
 Sporadic (%) 33 (67.3) 32 (54.2)  
 MEN2a/b (%) 16 (28.6) 27 (42.4)  
Stage     0.23
 I – III (%) 28 (10.2) 30 (16.1)  
 IV (%) 21 (42.9) 32 (51.6)  
Size mean in mm (SD) 26.1 (15.2) 25.1 (15.5) 0.75
 < 20mm (%) 20 (40.8) 22 (38.6) 0.84
 ≥ 20mm (%) 29 (59.2) 35 (61.4)  
Lymph node metastasis 28 (57.1) 42 (67.7) 0.32
Overall Survival 46 (93.9) 49 (79.0) 0.03
Progression Free Survival 42 (85.7) 38 (61.3) 0.01
Disease status     1.00
 Normal CEA/calcitonin (%) 17 (37.8) 22 (36.7)  
 Elevated CEA/calcitonin (%) 28 (62.2) 38 (63.3)  
Presence of necrosis 3 (6.2) 6 (10.0) 0.73
Presence of angioinvasion 4 (8.3) 6 (10.0) 1.00
Presence of desmoplasia     0.00
 None – some 32 (66.7) 20 (33.3)  
 Moderate – severe 16 (33.3) 40 (66.7)  
CAIX     0.34
 Neg (%) 29 (59.2) 30 (49.2)  
 Pos (%) 20 (40.8) 31 (50.8)  
Glut-1     0.23
 Neg (%) 48 (98.0) 57 (91.9)  
 Pos (%) 1 (2.0) 5 (8.1)  
MVD mean vessels/core 15.9 (9.7) 13.2 (5.8) 0.10
 < 14 vessels/core 22 (48.9) 35 (58.3) 0.43
 ≥ 14 vessels/core 23 (51.1) 25 (41.7)  
VEGF     0.41
 Neg (%) 18 (41.9) 20 (33.3)  
 Pos (%) 25 (58.1) 40 (66.7)  
Abbreviations: SD = Standard Deviation; MEN2a/b = Multiple Endocrine Neoplasia type 2a/b; CAIX = carbonic anhydrase 
IX; Glut-1 = glucose transporter 1.
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Table 2: Univariate Kaplan-Meier survival analysis on PFS and OS
 
 
Progression Free Survival Overall Survival
N PF (N) PF (%) p- value N OS (N) OS (%) p- value
Stage    0.00    0.14
 I-III 56 53 94.6  53 48 90.6  
 IV 52 24 46.2  49 38 77.6  
Gender    0.09    0.62
 Male 56 36 64.2  53 44 83.0  
 Female 52 11 78.8  49 42 85.7  
Tumor size    0.54    0.71
 < 20mm 40 33 82.5  39 34 87.2  
 ≥ 20mm 63 42 68.3  59 50 84.7  
Lymph node metastasis    0.00    0.09
 Yes 39 37 94.9  37 34 91.9  
 No 69 40 68.4  65 52 80.0  
Heritability    0.00    0.01
 Sporadic 62 40 64.5  57 45 78.9  
 MEN2a/b 43 36 83.7  42 39 92.9  
HIF-1α    0.01    0.04
 Neg 47 40 85.1  44 41 93.2  
 Pos 61 37 60.7  58 45 77.6  
Disease status    0.00    0.05
 Normal CEA/calcitonin 39 37 94.9  39 37 94.9  
 Elevated CEA/calcitonin 66 37 56.1  62 48 77.4  
Necrosis    0.01    0.01
 Neg 96 25 74.0  92 79 85.9  
 Pos 9 6 33.3  7 4 57.1  
Angioinvasion    0.18    0.67
 Neg 95 26 72.6  90 75 83.3  
 Pos 10 5 50.0  9 8 88.9  
Desmoplasia    0.16    0.30
 None – Some 51 10 80.4  49 44 89.8  
 Moderate – Severe 54 21 61.1  50 39 78.0  
CAIX    0.69    0.49
 Neg 59 45 76.3  58 51 87.9  
 Pos 48 32 66.7  43 34 79.1  
Glut-1    0.02    0.51
 Neg 102 74 72.5  97 81 83.5  
 Pos 6 3 50.0  5 5 100.0  
MVD    0.53    0.74
 < 14 58 39 67.2  54 45 83.3  
 ≥ 14 45 36 80.0  43 38 88.4  
VEGF    0.37    0.01
 Neg 37 26 70.3  34 32 94.1  
 Pos 64 48 75.0  61 49 80.3  
Abbreviations: N = number; PF = progression free; OS = overall survival; MEN2a/b = Multiple Endocrine Neoplasia type 
2a/b; CAIX = carbonic anhydrase IX; Glut-1 = glucose transporter 1.
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since this is predominantly base on postoperative CEA/
calcitonin measurements which are of value to evaluate 
over time to show tumor progression, but not as a single 
postoperative measurement, Glut-1 was left out as a down-
stream effector of HIF-1α; necrosis was left out since 
only 9 patients showed necrosis, and with a prevalence 
of only 8.1% it is not suitable as a prognostic factor. In 
this multivariate analysis, we found that HIF-1α positivity, 
TNM-stage IV and sporadic MTC were all significantly 
and independently correlated to PFS (Table 3). HIF-
1α positivity increased the risk of developing distant 
metastases with a HR of 3.1 (95% CI 1.3 – 7.3) per year. 
Hazard-ratios were 6.8 (95% CI 2.0 – 22.9) and 0.4 (95% 
CI 0.16 – 0.95) for Stage IV disease and MEN2a/MEN2b 
syndromes respectively. No violations of the proportional 
hazards assumption were found. In Figure 1A and 1B 
Kaplan-Meier curves visualize the prognostic effect of 
HIF-1α positivity and of Stage IV disease. In Figure 1C 
we show that also within TNM-stage IV disease, HIF-1α 
is able to identify patients with a less favorable outcome. 
Five-year survival rates were 55% for the HIF-1α positive 
group versus 95% for the HIF-1α negative group. Within 
the TNM-stage IV group survival decreased to 35% for the 
HIF-1α positive group versus 90% for the HIF-1α negative 
group.
DISCUSSION
This study shows that HIF-1α is associated with the 
disease course of MTC and could, therefore, be a valuable 
prognostic marker. Survival decreases significantly when 
Table 3: Multivariate cox-regression analysis on PFS
 Events/patients
Adjusted Hazard Ratio 
(95% CI) p-value
HIF-1α   0.01
 Negative 7/49 1  
 Positive 24/62 3.1 (1.3 – 7.3)  
Stage   0.00
 I-III 3/56 1  
 IV 28/52 6.8 (2.0 – 22.9)  
Heritability   0.04
 Sporadic 22/62 1  
 MEN2a/b 7/43 0.4 (0.16 – 0.95)  
Abbreviations: HIF-1α = Hypoxia Inducible Factor 1α; MEN2a/b = Multiple Endocrine Neoplasia type 2a/b.
Figure 1: 10-years PFS in Kaplan-Meier survival curve in patients with HIF-1α positive MTC compared to patients 
with HIF-1α negative MTC. (A) Analyses over total group of 111 patients comparing HIF-1α positive versus HIF-1α negative MTC. 
(B) Analyses over total group comparing TNM-stage I-IV. (C) Analyses over subpopulation of TNM-stage IV patients comparing HIF-1α 
positive versus HIF-1α negative MTC.
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HIF-1α was expressed, with five-year survival rates 
of 95% for HIF-1α positive MTC versus 55% for HIF-
1α negative MTC. As almost half of patients with MTC 
present with stage III-IV disease, indicating that the 
tumor already spread to either lymph nodes in the neck 
or to distant organs such as lung, liver or bones, a marker 
that can distinguish patients with a good survival within 
this group is warranted. Until now, prognostic markers in 
MTC that were identified, seemed to be of little clinical 
relevance, especially within the group with distant 
metastasis [12–16]. In contrast, HIF-1α did discriminate 
between less and more favorable prognosis within the 
group with TNM-stage IV in the present study.
Besides TNM-stage, CEA and calcitonin are well 
known valuable prognostic factors in MTC. In this study 
only direct postoperative measurements were included. 
CEA and calcitonin have the greatest prognostic value 
in the course of disease, i.e. faster doubling times give a 
worse prognosis [17, 18]. This means CEA and calcitonin 
are able to monitor tumor progression over time. However, 
we were more interested in pre- or postoperatively 
identifying patients who have a worse prognosis, thus 
identifying those patients who are likely to have short 
doubling times of CEA and calcitonin later on, to be able 
to prevent extensive tumor progression.
Koperek et. al. investigated HIF-1α expression in 
tumor tissue from 100 patients with sporadic MTC. They 
found expression of HIF-1α in 51% of cases, using the 
same threshold for HIF-1α positivity as we did. In line 
with their findings, our percentage of HIF-1α positivity 
was 56%. They did not show survival data, however 
correlations were found with variables that are known 
to correlate to poor prognosis i.e. grade of desmoplasia, 
T-stage and lymph node metastasis [11]. Our data 
confirmed their findings, since a significant correlation 
was found between HIF-1α expression and TNM-stage, 
lymph node metastasis and grade of desmoplasia.
Our study demonstrates that high HIF-1α expression 
in the primary MTC specimen is associated with poor 
outcome, especially in patients with advanced stage. 
Patients who are in need of a more intense follow-up 
can be identified, and this might have consequences for 
adjuvant therapeutic regimens. The prognostic value 
of HIF-1α in MTC is in line with findings in numerous 
studies performed in other cancer-types like; bladder 
-, breast -, cervical -, colorectal -, gastric -, head and 
neck -, non-small cell lung -, ovarian -, pancreatic -, 
prostate cancer and glioblastoma, glioma, melanoma, 
gastrointestinal stromal tumor and renal cell carcinoma. 
This has led to the generally accepted idea that increased 
expression of HIF-1α actively drives tumor growth and 
progression by regulating the expression of important 
target genes [10].
For CAIX expression only a weak-positive 
correlation was found with HIF-1α positivity. The 
relationship between CAIX and HIF-1α is complicated, 
since HIF-1α can also be upregulated by oxygen 
independent factors. This may effect the extent of their 
co-localization. Furthermore, the tissues examined are 
a 'snap-shot' in time, due to the very swift and dynamic 
kinetics of HIF-1α and the slower transcription of CAIX 
co-localization can be missed [19]. For Glut-1 a strong 
correlation (OR 4.2) was found, the lack of significance 
might be best explained by the relative low number of 
Glut-1 positive tumors (5.4%). Cytoplasmic staining 
of VEGF was seen in all MTCs however in a varying 
degree, we interpreted the VEGF staining as positive 
when there was a moderate to strong reactivity [20, 
21]. No significant correlation was found with HIF-1α, 
however VEGF is known to be upregulated by RET 
mutations and sporadic RET mutations are not included 
in our data [20]. However, we did find that patients with 
high VEGF expression had a significant shorter overall 
survival [22].
Figure 2: Representative examples of immunohistochemical staining pattern for HIF-1α, CAIX, Glut-1, VEGF and 
MVD. (A) HIF-1α nuclear staining pattern in 50% of cells, (B) focal membranous CAIX immunoreactivity, (C) focal membranous 
Glut-1 immunoreactivity, (D) strong cytoplasmic VEGF immunoreactivity, (E) high MVD shown by CD31 immunoreactivity, (F) absent 
HIF-1α staining, (G) absent CAIX staining, (H) absent Glut-1 in tumor cells, with control positivity in red blood cells, (I) weak VEGF 
immunoreactivity, (J) MVD is 0 shown by absence of CD31 immunoreactivity.
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Our results also raise interest in targeting HIF-1α 
in MTC. Targeting hypoxia is challenging. There are in 
short two main approaches: bioreductive prodrugs and 
inhibition of molecular targets in hypoxic cells. The main 
advantage of the bioreductive prodrugs is the ability to, 
selectively, attack hypoxic cells, resulting in a low toxicity 
profile. Therefore, they have a greater opportunity for a 
combination with current standards of therapy; Vandetanib 
and Cabozantinib [23]. However, the present study is 
merely a prognostic one, and further in vitro - and in vivo 
studies should be developed to investigate the role of 
bioreductive prodrugs in combination with tyrosine kinase 
inhibitors in MTC.
One of the strengths of this study is the fact that 
we combine immunohistochemical data with clinical 
endpoints such as survival or the occurrence of distant 
metastases in a relatively large sample size. Furthermore, 
since MTC is in most cases a relatively low-proliferating 
tumor, event-rates are low and a long follow-up is 
needed to detect them. Our follow-up is long (mean 
70.2 months; SD 60.6) and we used PFS to increase the 
total number of events. One of the limitations is that 
immunohistochemistry is inherently a more qualitative 
than quantitative method. Furthermore, one might argue 
that due to heterogeneity of the HIF-1α, CAIX and 
Glut-1 staining pattern the use of tissue microarrays is 
suboptimal. However, studies investigating concordance 
between whole slide analysis and TMA results found good 
concordance in general [24]. Moreover, tissue microarrays 
are described as the standard for the validation of 
prognostic biomarkers [25, 26] and have been used in 
studies investigating the same proteins [27–30]. Further 
limitations are merely due to its retrospective character 
and the low incidence of MTC. A total of 5 tertiary referral 
centers have participated and patients over almost 3 
decades have been included. To overcome this we limited 
our analyses to variables least subject to treatment changes 
overtime or interinstitutional differences.
In summary, HIF-1α overexpression is a prognostic 
biomarker in MTC indicating a worse prognosis, 
particularly, in the subpopulation with TNM-stage IV. 
Thus, HIF-1α may be clinically useful to identify patients 
in need of more intense follow-up or adjuvant therapy, and 
may provide an interesting therapeutic target in MTC.
MATERIALS AND METHODS
Patients
Patients who underwent surgery between 1988 
and 2014 for MTC were identified from the pathology 
databases of Leiden University Medical Center (LUMC), 
Amsterdam Medical Center (AMC), Radboud University 
Medical Center (RadboudUMC), University Medical 
Center Groningen (UMCG) and University Medical 
Center Utrecht (UMCU), The Netherlands (all tertiary 
referral centers). Formalin fixed paraffin embedded 
(FFPE) tissues were collected from the pathology 
archives. In total 111 patients were identified from who 
primary tumor tissue was available for inclusion in the 
tissue microarray (TMA).
Whole slides were scored for necrosis, angioinvasion 
and desmoplasia. Necrosis and angioinvasion were scored 
as absent or present and desmoplasia as negative, some, 
moderate or severe. These scorings were performed on the 
same FFPE blocks that were used for the construction of 
the TMA.
Clinical and pathological patient information 
was retrieved from patient files in all five centers. All 
MEN2 diagnoses were confirmed by germline mutation 
analysis, sporadic patients were either patients with 
negative germline mutation analysis or with a negative 
family history. Microscopic positive resection margins 
were considered as part of the T-stage and not included 
as a separate variable. Disease status was based on 
postoperative calcitonin and CEA measurements; this 
was scored as a dichotomous variable. Since we included 
patients from five centers over almost three decades 
different assays were used for CEA and calcitonin 
measurements, therefore making it impossible to compare 
exact values. An elevation in CEA or calcitonin was 
interpreted as persistent disease, an CEA or calcitonin 
within normal range was interpreted as cured. Only 
postoperative CEA and calcitonin measurements were 
taken into account. Due to the fact that CEA and calcitonin 
measurements were performed in five centers over almost 
three decades and different assays were used, doubling 
times could not reliably be assessed. This study was 
performed according to national guidelines with respect 
to the use of leftover tissue [31] and approval for this 
study was obtained from the Institutional Review Board 
of the UMCU.
Construction of tissue microarray
The TMA was developed on the TMA machine 
(TMA grand master, 3D Histec, Budapest, Hungary). 
Three cores of 0.6 mm were punched from FFPE blocks 
of the primary tumor. To assure that cores were punched 
from tumor areas, cell rich areas were marked on H&E 
slides by a pathologist (PJvD), scanned, and marks were 
manually circled with the TMA software (3D Histech). In 
this manner cell rich punches were automatically inserted 
into the recipient block.
Immunohistochemistry
After deparaffinization and rehydration, endogenous 
peroxidase was blocked in a buffer solution containing 
0.3%hydrogen peroxidase for 15 minutes. For HIF-1α 
antigen retrieval was performed using EDTA buffer, 
pH = 9.0, at boiling temperature for 20 minutes. A 
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cooling period of 30 minutes preceded the incubation 
of the slides with protein block (Novolink Max Polymer 
detection system, ready to use, Novocastra Laboratories 
Ltd, Newcastle Upon Tyne, UK) for 5 minutes at room 
temperature. Incubation of the slides with the HIF-
1α mouse monoclonal (BD Biosciences, Pharmingen, 
Lexington, MA, USA), was done at a dilution of 1:50 
overnight at 4°C. For detection a polymer (Novolink Max 
Polymer detection system, ready to use, post primary for 
30 minutes and Novolink Polymer for 30 minutes) was 
used and developed with diaminobenzidine (5 minutes, 
Novolink Polymer detection system). For Glut-1, CAIX 
and VEGF-A, downstream targets of HIF-1α, antigen 
retrieval was performed in citrate buffer, pH = 6.0, for 20 
minutes at boiling temperature. For Glut-1 and CAIX, a 
cooling period of 30 minutes preceded the incubation (60 
minutes at room temperature) with the primary antibodies. 
Polyclonal primary antibodies used were Glut-1 (1:200, 
DAKO, Santa Clara, USA) and CAIX (1:1000, Abcam, 
Cambridge Science Park, Cambridge, UK). For VEGF-A, 
a cooling period of 30 minutes preceded the incubation 
of the slides with the VEGF-A rabbit polyclonal antibody 
(0.2 μg/mL, RB-9031, ThermoFisher, Fremont, USA)
[32]. For detection of the primary antibodies a poly HRP 
anti- Mouse/Rabbit/Rat IgG (Brightvision ready to use, 30 
minutes. ImmunoLogic, Duiven, The Netherlands) was 
used. All slides were developed with diaminobenzidine (10 
minutes) followed by hematoxylin counterstaining. Before 
the slides were mounted, all sections were dehydrated in 
alcohol and xylene. Positive and negative controls were 
used throughout. 
To calculate microvessel density (MVD) CD31 
immunohistochemistry was performed on the automatic 
system (BenchMark ULTRA, Ventana Medical System, 
Tucson, Arizona). The CD31 mouse monoclonal antibody, 
clone JC70A (1:100, DAKO, Santa Clara, USA).
Scoring of immunohistochemistry
All TMA slides were scored by an experienced 
pathologist (PJvD) and an experienced researcher 
(LL), when there was inconsistency between both a 2nd 
experienced pathologist was consulted. For HIF-1α 
the percentage of positive nuclei per core was scored 
as an absolute number. For statistical analysis this was 
transformed in a dichotomous variable, which was positive 
when in either one of the three cores ≥1 percent of nuclei 
were positive as previously used [8, 11, 27]. Glut-1 and 
CAIX were scored as absent, cytoplasmic or membranous 
for each core separately. For statistical analysis only 
membranous staining was taken into account, when this 
was present for either one of the cores the tumor was 
considered positive [8]. VEGF-A was scored as absent 
(0), weak (1), moderate (2) or strong (3) for each core 
separately. For statistical analysis the average score 
over three cores was calculated and when this was ≥2 
it was considered positive. MVD was calculated by the 
average number of CD31 positive vessels per core. For 
the dichotomous variable of CD31, a cut-off of 14 (mean) 
was chosen. Representative scores of all immunostainings 
are shown in Figure 2.
Statistical analysis
Categorical data were summarized with frequencies 
and percentages, and continuous data were summarized 
with medians and ranges. Progression was defined as 
development of distant metastases or dead. This excluded 
development of lymph node metastases or elevation in 
CEA/calcitonin. We chose this definition since MTC 
is an incurable disease when distant metastases occur. 
Progression-free survival (PFS) was therefore defined as 
the time to development of distant metastases or dead. To 
increase the power of the statistical analysis categorical 
data were recoded into dichotomous variables. Stage 
I, II, III and IV was recoded into stage I - III and stage 
IV; hereditability was recoded in either sporadic or 
hereditable; grade of desmoplasia was recoded in none - 
some and moderate - severe.
The chi-square test was used to assess associations 
between the dichotomous variables, the Student's t-test 
was used to test for differences between continuous 
variables. Kaplan-Meier survival curves were plotted, and 
univariate survival analysis was performed and the log-
rank test was used to calculate significance. Multivariate 
Cox-regression analysis was performed and Hazard 
Ratios (HR) of clinicopathologic characteristics on PFS 
were calculated. Violations of the proportional hazards 
assumption were tested by the log minus log plot and by 
adding a time dependent covariate. All reported p-values 
were two sided. Analysis was performed using SPSS 
version 22.0 software (SPSS, Inc., Chicago, IL, USA).
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